<DOC>
	<DOCNO>NCT00107484</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , magnetic resonance imaging ( MRI ) use ferumoxtran-10 , may help find diagnose breast cancer may spread axillary lymph node may help plan breast cancer treatment . PURPOSE : This phase II trial study well MRI use ferumoxtran-10 work find metastasis axillary lymph node patient invasive breast cancer .</brief_summary>
	<brief_title>Magnetic Resonance Imaging Using Ferumoxtran-10 Finding Metastases Axillary Lymph Nodes Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine utility magnetic resonance ( MR ) image use ferumoxtran-10 identifying metastasis axillary lymph node patient invasive breast cancer . Secondary - Determine change MR T1 T2 signal intensity primary breast tumor administration drug patient . - Determine potential delay imaging , term define tumor boundary , patient . OUTLINE : Patients receive ferumoxtran-10 IV 25-30 minute day 0 absence unacceptable toxicity . Patients undergo MRI involve breast ipsilateral axilla day 0 ( ferumoxtran-10 administration ) day 1 . Within 3 week completion image study , patient undergo sentinel lymph node biopsy . If sentinel node positive malignancy touch prep , axillary lymph node dissection perform clinically indicate . Patients follow approximately 1 month surgery . PROJECTED ACCRUAL : A total 50 patient accrue study within 8.3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm invasive breast cancer Candidate sentinel lymph node biopsy and/or axillary lymph node dissection Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status Not specify Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Ferritin ≤ 350 ng/mL* Transferrin saturation level ≤ 40 % * NOTE : *Patients lab value limit may eligible provided hemochromatosis hematology consultation Hepatic Bilirubin normal AST ALT ≤ 2.5 time upper limit normal Alkaline phosphatase normal PT normal Albumin normal No history cirrhosis Renal Creatinine normal OR Creatinine clearance &gt; 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Medically stable No ongoing active infection No history allergic reaction attribute compound similar chemical biological composition ferumoxtran10 ( e.g. , iron preparation , parenteral iron , parenteral dextran , parenteral irondextran , parenteral ironpolysaccharide preparation ) No history allergic reaction contrast medium No immunodeficiency would predispose patient specific nonspecific mediator release No contraindication MRI , include follow : Severe claustrophobia Pacemaker Aneurysm clip Defibrillators Certain type replacement joint Other institutional contraindication MRI No psychiatric illness social situation would preclude study compliance No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 30 day since prior investigational agent More 3 month since prior ferumoxides</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>